United States Pharmaceuticals and Healthcare Report Q1 2015

United States Pharmaceuticals and Healthcare Report Q1 2015

BMI View:

In the face of increasing product launches within highly-competitive therapeutic areas such as diabetes care in the US, payers are becoming ever more confident in leveraging their purchasing power over pharmaceutical companies. With few differentiating factors between competing products, pharmacy benefit managers and health insurers are in a position to secure better deals for themselves.

Headline Expenditure Projections

- Pharmaceuticals: USD347.2bn in 2013 to USD354.2bn in 2014; 2.0% growth. Forecast revised upwards from Q414.
- Healthcare: USD2,918bn in 2013 to USD3,099bn in 2014; +6.2% growth. Forecast revised upwards from Q414.
BMI Industry View 7
SWOT 9
Political 11
Economic 12
Industry Forecast 13
Pharmaceutical Market Forecast 13
Table: Pharmaceutical Sales, Historical Data And Forecasts (United States 2010-2018) 14
Healthcare Market Forecast 15
Table: Healthcare Expenditure Trends, Historical Data And Forecasts (United States 2010-2018) 17
Table: Government Healthcare Expenditure Trends, Historical Data And Forecasts (United States 2010-2018) 17
Table: Private Healthcare Expenditure Trends, Historical Data And Forecasts (United States 2010-2018) 18
Prescription Drug Market Forecast 18
Table: Prescription Drug Market Indicators, Historical Data And Forecasts (United States 2010-2018) 20
Table: Number Of Dispensed Prescriptions By Therapy Area In The US (mn) 20
Table: Number Of Dispensed Prescriptions By Active Ingredient In The US (mn) 21
Patented Drug Market Forecast 22
Table: Patented Drug Market Indicators, Historical Data And Forecasts (United States 2010-2018) 23
Table: Leading Patented Medicines By Non-Discounted Sales In The US (USDbn) 23
Table: Leading Therapeutic Classes By Non-Discounted Sales (USDbn) 24
Generic Drug Market Forecast 25
Table: Generic Drug Market Indicators, Historical Data And Forecasts (United States 2010-2018) 27
OTC Medicine Market Forecast 27
Table: Over-The-Counter (OTC) Medicine Market Indicators, Historical Data And Forecasts (United States 2010-2018) 29
Pharmaceutical Trade Forecast 29
Table: Pharmaceutical Trade Data And Forecasts (United States 2012-2018) 30
Key Risks To BMI's Forecast Scenario 31
Macroeconomic Forecasts 32
Economic Analysis 32
Table: Economic Activity (United States 2009-2018) 38
Industry Risk Reward Ratings 39
Americas Risk/Reward Index 39
United States Risk/Reward Index 45
Rewards 45
Risks 45
Market Overview 47
Industry Trends And Developments 50
Epidemiology 50
Healthcare Sector 51
Table: Key Features Of The Affordable Care Act By Year 53
Impact Of The Sequester 55
Research And Development 56
Clinical Trials 57
Contract/Clinical Research Organisations 58
Hospital Sector 59
Regulatory Development 61
Intellectual Property Regulations 75
Pricing And Reimbursement Environment 76
Late-2013 Government Shutdown 79
Competitive Landscape 81
Pharmaceutical Sector 81
Pharmaceutical Distribution 82
Pharmaceutical Retail Sector 83
Company Profile 85
Pfizer 85
Merck 89
Eli Lilly 92
Amgen 95
GlaxoSmithKline 98
AstraZeneca 102
Demographic Forecast 107
Table: Population Headline Indicators (United States 1990-2025) 108
Table: Key Population Ratios (United States 1990-2025) 108
Table: Urban/Rural Population & Life Expectancy (United States 1990-2025) 109
Table: Population By Age Group (United States 1990-2025) 109
Table: Population By Age Group % (United States 1990-2025) 110
Glossary 112
Methodology 114
Pharmaceutical Expenditure Forecast Model 114
Healthcare Expenditure Forecast Model 114
Notes On Methodology 115
Risk/Reward Index Methodology 116
Index Overview 117
Table: Pharmaceutical Risk/Reward Index Indicators 117
Indicator Weightings 118
Loading...

We are very sorry, but an error occurred.
Please contact support@reportbuyer.com if the problem remains.